90 related articles for article (PubMed ID: 18989897)
1. Potential of different techniques of preferential crystallization for enantioseparation of racemic compound forming systems.
Polenske D; Lorenz H; Seidel-Morgenstern A
Chirality; 2009 Aug; 21(8):728-37. PubMed ID: 18989897
[TBL] [Abstract][Full Text] [Related]
2. Application of preferential crystallization to resolve racemic compounds in a hybrid process.
Lorenz H; Polenske D; Seidel-Morgenstern A
Chirality; 2006 Nov; 18(10):828-40. PubMed ID: 16917833
[TBL] [Abstract][Full Text] [Related]
3. A hybrid process for chiral separation of compound-forming systems.
Gou L; Robl S; Leonhard K; Lorenz H; Sordo M; Butka A; Kesselheim S; Wolff M; Seidel-Morgenstern A; Schaber K
Chirality; 2011 Feb; 23(2):118-27. PubMed ID: 20845428
[TBL] [Abstract][Full Text] [Related]
4. Solubility, metastable zone width, and racemic characterization of propranolol hydrochloride.
Wang X; Wang XJ; Ching CB
Chirality; 2002 May; 14(4):318-24. PubMed ID: 11968072
[TBL] [Abstract][Full Text] [Related]
5. Experimental study and simplified mathematical description of preferential crystallization.
Elsner MP; Fernández Menéndez D; Muslera EA; Seidel-Morgenstern A
Chirality; 2005; 17 Suppl():S183-95. PubMed ID: 15856522
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-assisted physicochemical enantioseparation processes-Part III: Overcoming yield limitations by dynamic kinetic resolution of asparagine via preferential crystallization and enzymatic racemization.
Würges K; Petrusevska-Seebach K; Elsner MP; Lütz S
Biotechnol Bioeng; 2009 Dec; 104(6):1235-9. PubMed ID: 19655380
[TBL] [Abstract][Full Text] [Related]
7. Solubility and some crystallization properties of conglomerate forming chiral drug guaifenesin in water.
Fayzullin RR; Lorenz H; Bredikhina ZA; Bredikhin AA; Seidel-Morgenstern A
J Pharm Sci; 2014 Oct; 103(10):3176-82. PubMed ID: 25091705
[TBL] [Abstract][Full Text] [Related]
8. Propagation of biochirality: crossovers and nonclassical crystallization kinetics of aspartic acid in water.
Lee T; Lin YK; Tsai YC; Lee HL
Chirality; 2013 Nov; 25(11):768-79. PubMed ID: 23873735
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous Chiral Resolution of Two Racemic Compounds by Preferential Cocrystallization*.
Zhou F; Shemchuk O; Charpentier MD; Matheys C; Collard L; Ter Horst JH; Leyssens T
Angew Chem Int Ed Engl; 2021 Sep; 60(37):20264-20268. PubMed ID: 34233036
[TBL] [Abstract][Full Text] [Related]
10. The separation of racemic crystals into enantiomers by chiral block copolymers.
Mastai Y; Sedlák M; Cölfen H; Antonietti M
Chemistry; 2002 Jun; 8(11):2429-37. PubMed ID: 12180321
[TBL] [Abstract][Full Text] [Related]
11. Three different types of chirality-driven crystallization within the series of uniformly substituted phenyl glycerol ethers.
Bredikhin AA; Bredikhina ZA; Novikova VG; Pashagin AV; Zakharychev DV; Gubaidullin AT
Chirality; 2008 Nov; 20(10):1092-103. PubMed ID: 18767134
[TBL] [Abstract][Full Text] [Related]
12. Resolution of Racemic Guaifenesin Applying a Coupled Preferential Crystallization-Selective Dissolution Process: Rational Process Development.
Temmel E; Eicke MJ; Cascella F; Seidel-Morgenstern A; Lorenz H
Cryst Growth Des; 2019 Jun; 19(6):3148-3157. PubMed ID: 32952448
[TBL] [Abstract][Full Text] [Related]
13. A Comparative Study of Coupled Preferential Crystallizers for the Efficient Resolution of Conglomerate-Forming Enantiomers.
Majumder A; Nagy ZK
Pharmaceutics; 2017 Dec; 9(4):. PubMed ID: 29206148
[TBL] [Abstract][Full Text] [Related]
14. Online monitoring of preferential crystallization of enantiomers.
Alvarez Rodrigo A; Lorenz H; Seidel-Morgenstern A
Chirality; 2004 Oct; 16(8):499-508. PubMed ID: 15290684
[TBL] [Abstract][Full Text] [Related]
15. Preferential enrichment: significant influence of minor molecular modification on the mode of polymorphic transition during crystallization.
Fujimoto D; Takahashi H; Ariga T; Tamura R
Chirality; 2006 Feb; 18(3):188-95. PubMed ID: 16432918
[TBL] [Abstract][Full Text] [Related]
16. Enabling Direct Preferential Crystallization in a Stable Racemic Compound System.
Harfouche LC; Brandel C; Cartigny Y; Ter Horst JH; Coquerel G; Petit S
Mol Pharm; 2019 Nov; 16(11):4670-4676. PubMed ID: 31545612
[TBL] [Abstract][Full Text] [Related]
17. Racemic compound against racemic conglomerate formation: the crystal properties of allylbenzylmethylphenylphosphonium iodide as compared with the nitrogen analogue.
Bredikhin AA; Eliseenkova RM; Bredikhina ZA; Dobrynin AB; Kostyanovsky RG
Chirality; 2009 Jul; 21(7):637-41. PubMed ID: 18853466
[TBL] [Abstract][Full Text] [Related]
18. Shortcut Model for Describing Isothermal Batch Preferential Crystallization of Conglomerates and Estimating the Productivity.
Carneiro T; Bhandari S; Temmel E; Lorenz H; Seidel-Morgenstern A
Cryst Growth Des; 2019 Sep; 19(9):5189-5203. PubMed ID: 32952449
[TBL] [Abstract][Full Text] [Related]
19. Separation of Etiracetam Enantiomers Using Enantiospecific Cocrystallization with 2-Chloromandelic Acid.
Nulek T; Klaysri R; Cedeno R; Nalaoh P; Bureekaew S; Promarak V; Flood AE
ACS Omega; 2022 Jun; 7(23):19465-19473. PubMed ID: 35721919
[TBL] [Abstract][Full Text] [Related]
20. Enantioseparation by crystallization using magnetic substrates.
Tassinari F; Steidel J; Paltiel S; Fontanesi C; Lahav M; Paltiel Y; Naaman R
Chem Sci; 2019 May; 10(20):5246-5250. PubMed ID: 31191879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
